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Abstract
Background: In our recent village-based cross-sectional study, the prevalence of nucleic acid amplification
technique (NAAT) diagnosed Chlamydia trachomatis (CT) in sexually active Samoan women was very high (36 %),
and test positivity was associated with sub-fertility. We conducted a serological and epidemiological analysis in
these participants to identify if serological data can provide further insight into the potential contribution of CT to
sub-fertility in this population.
Methods: Serological prediction of CT associated sub-fertility was conducted using a series of commercial tests.
The correlation between fertility or sub-fertility, behavioral factors, and serologically predicted CT associated sub-
fertility was determined.
Results: A positive antibody reaction against the Chlamydia Major Outer Membrane Protein (MOMP) was
significantly associated with sub-fertility, with 50 % of infertile women being positive. Serum IgG and IgA antibodies
against MOMP correlated with current infection measured by urine NAAT, suggesting longer term infections are
common in this population. Chlamydia pneumoniae antibodies were frequently detected in this population (84 %),
and unexpectedly, were significantly associated with sub-fertility.
Conclusions: The high prevalence of chlamydial infection and of positive chlamydial sub-fertility results suggests
that CT is an important and frequent contributory factor to sub-fertility in this population.
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Background
Chlamydia trachomatis (CT) is the most common bac-
terial sexually transmitted infection (STI) in the world.
The infection can result in the development of serious
sequelae such as pelvic inflammatory disease (PID), ec-
topic pregnancy and tubal factor infertility (TFI) in
women. The reported prevalence of CT infection is in
the range 1.4–8.7 % when the general population in high
income countries is screened [1–3]. The prevalence of
CT infection in Samoa was previously estimated by
Sullivan et al. [4] to be 30.9 % based on antenatal screen-
ing. Similarly, in women who attended antenatal clinics
between 2004 and 2005 in the Pacific Islands (Fiji,
Kiribati, Samoa, Solomon Islands, Tonga, and Vanuatu),
CT prevalence was 26.1 % in women under 25 years old,
and 11.9 % in women over 25 [5].
The proportion of infertility attributable to CT in the
Samoan population is not known. Such infertility results
from tissue damage to the fallopian tubes (tubal factor in-
fertility, TFI) that remains after the active infection is
cleared, meaning that diagnosis using nucleic acid amplifi-
cation tests (NAAT) is not necessarily suitable. There are
numerous serological or chlamydia antibody tests (CAT)
that have been developed to diagnose CT infertility, that
have been validated on cohorts of women with evidence
of tubal damage detected by hysterosalpingography or
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laparoscopy [6–11]. In a meta-analysis of published evalu-
ations of various assays, Broeze and co-workers identified
that micro immune-fluorescence (MIF) was the most sen-
sitive, but relatively low in specificity [6]. In the same
study the MEDAC and ANIlabsystems enzyme linked
immunosorbant assays (ELISA) appeared to most specific,
although less sensitive than MIF, to diagnose women with
uni or bi-lateral tubal damage detected by surgical or
sonographic technologies [6]. However, a proportion of
women with infertility and who are serologically positive
by CAT have no detectable tubal blockage but still require
IVF (in vitro fertilization) to conceive, and this could be at
least partially due to tubal damage not detectable by the
current surgical or sonographic methods [7, 12–14]. In
lower and middle income countries (LMIC) studies gener-
ally report higher prevalence of CT in infertile or sub-
fertile women (39-55 %), although the prevalence of CT
infection in fertile women is also generally high [15–17].
We recently reported a high prevalence (36.0 % by
NAAT) of CT in Samoan women using community-
based screening and survey of sexually active women
aged 18–29 years having unprotected sex, and current
infection was associated with women who were defined
as being sub-fertile [14, 18]. Here, we conducted a sero-
logical study to evaluate the prevalence of CT associated
sub-fertility in these same women.
Methods
The study design and sampling protocol has been previ-
ously reported [15, 18]. Women (n = 239) were recruited
into a cross-sectional study on CT and sub-fertility from
the Pacific nation of Samoa during 2011. Participant inclu-
sion criteria were age between 18 and 29 years, living in
the village for at least a year and being sexually active
without using any forms of contraception (including con-
doms, birth control pills, or other forms of contraception)
for at least a year. Women were excluded if they had a
medical condition, or had undergone a procedure that
made it impossible to become pregnant. Participants
provided informed written consent, completed an
interviewer-led questionnaire and provided biological
samples. The nurse who conducted the interview asked
the sexual behavioral questions using socially acceptable
language and used a two step approach to gauge sexual
behavior (as previously described) [18]. The question-
naire responses were used to assign women to ‘sub-fer-
tile’ (or otherwise ‘fertile’). Sub-fertility was defined as
at least 12 months of unprotected intercourse without
conceiving a pregnancy [18]. The NAAT results have
been previously analysed and presented [18], all partici-
pants provided a urine specimen that was analysed for
CT infection status using the BD ProbeTec ET assay in
accordance with the manufacturer’s instructions and
using positive and negative controls (BD Biosciences,
USA) [18].
The participant sera were tested for CT antibodies
using the following commercial ELISAs: CT-IgG ELISA-
plus MEDAC (peptides from the MOMP protein, re-
ferred to as MEDAC MOMP, used to diagnose past or
current infection), cHSP60-IgG ELISA MEDAC (cSHP60
protein), ANIlabsystems CT IgG (peptides from MOMP,
marketed to diagnose CT infertility), CT IgA ELISA
MEDAC (used to diagnose current CT infection), Chla-
mydia pneumoniae (CP)-IgG-ELISA MEDAC (used to
diagnose current CP infection) (summarized in Table 1).
The assay positive or negative results in accordance with
the manufacturer’s instructions were used for this study
(positive, negative, unequivocal (excluded), invalid (ex-
cluded)). Titres were not included in this study as they
are not part of these commercial tests. All sera were
tested with all assays, however, any that were unequivo-
cal or invalid more than once were excluded from the
data for that assay and any participants that did not have
a complete dataset and valid test result in every assay
were completely excluded from the analysis in Table 2
and Fig. 2. The serological testing of CT associated sub-
fertility is difficult because the gold standard (MIF) has
low specificity leading to high false positives (although it
had the highest accuracy using area under the curve),
but is reported to be highly subjective and labor inten-
sive [6]. Therefore we chose to test the population using
ELISA as we prioritised highest specificity in order to
Table 1 Commercial serological assays and previously reported sensitivity and specificity
Assay name Antigen Study reference name Sensitivity Specificity Detected group Ref
MEDACCT-IgG ELISA-plus MEDAC MOMP MEDAC MOMP 55 % 87 % Women with infertility (n = 315) [7]
cHSP60-IgG ELISA MEDAC cHSP60 MEDAC cHSP60 69 % 93 % Women with TFI (n = 70) [22]
MEDAC IgG CT pELISA
and cHSP60 IgG ELISA
Combination of
both assays
MEDAC Infertile [22]
ANIlabsystems CT IgG MOMP peptides ANIlab 91 % 84 % CT NAAT diagnosed infection and
infertility (n = 303)
[16]
CT IgA ELISA MEDAC MOMP peptides MEDAC IgA NAAT diagnosed current infection [23]
C. pneumoniae-IgG-ELISA MEDAC MOMP peptides MEDAC Cpn 91.3 % 93.3 % Current pneumonia and MIF positive
status for C. pneumoniae
[24]
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indicate the amount of CT associated sub-fertility in
Samoa, and a format that could enable us to compare
several tests in a timely manner. We selected multiple
ELISAs to compare the different IgG responses and we
also included IgA to indicate how many of the infections
were recent. Finally, we included a Chlamydia pneumo-
niae ELISA to enable comparison of the sero-prevalence
of a related and very common pathogen.
All statistical analyses were conducted in R statistical
environment (3.0.3) using the ‘EpiR (0.9-57) and 'meta-
for' package (1.9-2) for calculation and presentation
(forest plots) of odds ratios (OR). All analyses were con-
ducted to measure the association of assay results with
sub-fertility. OR and 95 % confidence intervals (CI) were
calculated with restricted maximum likelihood estimates
of error.
Results
Antibody test results for CT associated sub-fertility
Two hundred thirty-nine women meeting the inclusion
and exclusion criteria participated in the study; 90 were
defined as being sub-fertile and 149 were defined as fer-
tile with a history of having had a pregnancy. The associ-
ation of CT with sub-fertility was analysed using each of
the commercial serological assays. As shown in Fig. 1a,
women who were sub-fertile were significantly more
likely to have a positive serological reaction in the
MEDAC MOMP assay (p = 0.045). 42 out of 82 sub-fertile
women were positive in the MEDAC MOMP assay,
whereas 52 out of a total of 139 fertile women were posi-
tive. It is important to note that 34 sub-fertile women have
been excluded for this assay from Fig. 1a because they had
unequivocal results. One of the most common immuno-
logical reactions that was associated with infertility in pre-
vious studies [9, 12], an antibody response to cHSP60, was
not significantly associated with sub-fertility: the sero-
prevalence of antibodies to cHSP60 did not differ based
on fertility with 57 % of both infertile and fertile women
being positive (44 out of 76 sub-fertile women were posi-
tive and 73 out of 129 fertile women were positive). The
Table 2 Participant data included/excluded in the Table 3
analysis
Variable Included, n Excluded, n OR (95 % C.I.) P value for OR
Age
18–24 97 48 1
25–29 64 29 1.11 (0.63–1.94) 0.720
Smoking
Never 129 59 1
Ex-smoker/
current
33 18 0.84 (0.44–1.61) 0.600
Fertility status
Sub-fertile 59 28 1
Fertile 103 49 1.00 (0.57–1.75) 0.990
Comparison of Age, smoking and fertility status for participants included or
excluded in the study. Participants excluded had no statistical difference in
age, smoking or fertility status (P > 0.05)
Fig. 1 Analysis of the association of serological responses to Chlamydia with fertility and CT infection status. a. The figure shows Forest plots and
Odds Ratio of the association of a positive reaction in the serological assay listed to the right with being infertile. The assay is indicated in the left
column. The number of participants that were positive or negative in the serum assay(s) according to their fertile or infertile status are shown on
the figure. All 239 participant specimens were tested in each assay. Samples that were unequivocal or not reproducible upon multiple testing
were excluded for each assay and these are indicated in the column titled invalid/unequivocal on the table. b. The number of participants
positive or negative in each serological assay, grouped according to also being positive or negative for current CT infection by urine NAAT
(Chlamydia +/−) are shown on the figure. OR with 95 % CI and P values are indicated at the right of the figures
Menon et al. BMC Infectious Diseases  (2016) 16:175 Page 3 of 7
MEDAC Infertile assay, which is recommended by the
manufacturer to be a positive reaction in both the
MEDAC MOMP and MEDAC cHSP60 assays, was not
significantly associated with sub-fertility in this study (in
the infertile group 29 women were positive out of 74 total
who had results in the assay, and 36 were positive out of a
total of 127 women with reportable results in the fertile
group).
The overall IgG sero-positivity to CT in this popu-
lation was 43 % according to the MEDAC MOMP re-
sults, and 50 % according to the ANIlab assay. The
numbers reported in Fig. 1 vary depending on the
number of women that had consistent reportable re-
sults in the assay (i.e. we did not include unequivocal
or invalid results, these are indicated to the left of
the figure).
We included testing for a common respiratory pathogen
(Chlamydia pneumoniae) to provide an indication of sero-
logical responses in our population tested. Women who
were sub-fertile were significantly more likely to have a
positive reaction in MEDAC CP assay (p < 0.001) (Fig. 1a).
The overall presence of sero-positivity to this pathogen
(CP) was 86 %. A positive urine NAAT result did not cor-
relate with a positive CP serological result, supporting that
this assay is not likely to be detecting CT cross reactivity.
Although, pairwise analysis did show that MEDAC
MOMP positivity significantly correlated with MEDAC
CP (chisel p = 0.042), meaning that women positive in
MEDAC MOMP were more likely to be positive in
MEDAC CP (OR 3.63 [95 % CI: 0.92–21.11]).
We previously reported that the current infection
by urine NAAT was 36 % in this cohort [18], there-
fore, we evaluated if the serological results correlate
with current infection status. Women who were
NAAT positive were significantly more likely to be
positive in the serological assays for CT by all of as-
says tested (Fig. 1b). The high association of IgG
against MOMP and cHSP60 and current infection by
urine NAAT in this cohort could imply these are lon-
ger term infections, consistent with the lack of STI
screening and treatment programs in this country. A
positive result in the MEDAC IgA significantly corre-
lated with NAAT positive status (Fig. 1b) (p = 0.004).
This higher frequency of IgG (compared to IgA) cor-
relating with NAAT diagnosed current infection fur-
ther supports the possibility that in this population
there are frequent repeat or longer term infections,
given that IgA tends to be produced early and in pri-
mary infections.
In the evaluation of demographic factors in relation to
subfertility and serological results, we only included data
for participants that had a recordable result in every test
and answered every demographic question (n = 162).
The details of the participants excluded from this
analysis are provided in Table 2, and there were no sig-
nificant differences in the sub-fertility status or other
factors in those excluded compared to those included.
Age (older women were more likely to be fertile, p <
0.010), MEDAC MOMP (p = 0.040), NAAT positive for
CT (p = 0.003) and MEDAC CP (p = 0.007) were all sig-
nificant factors that associated with sub-fertility in this
subset of participants (Table 3).
We used the same subset of specimens to assess test
concordance. As shown in the Venn diagram (Fig. 2)
there was often concordance between the serological
Table 3 Analysis of demographic factors and serological results
that associate with sub-fertility
Variable Sub-fertile,
n
Fertile,
n2a
OR
(95 % C.I.)
P value
for OR
Age
18–24 47 50 1
25–29 12 53 0.24 (0.11–0.51) <0.01
BMI
Normal Weight 12 21 1
Overweight 27 35 0.74 (0.31–1.80) 0.498
Obese 20 47 0.74 (0.31–1.80) 0.512
Smoking
Never 46 83 1
Ex-smoker/current 13 20 1.17 (0.53–2.57) 0.691
MEDAC Infertile
Negative 34 72 1
Positive 25 31 1.71 (0.88–3.33) 0.115
MEDAC MOMP
Negative 28 66 1
Positive 31 37 1.97 (1.03–3.78) 0.040
MEDAC cHSP60
Negative 25 41 1
Positive 34 62 0.9 (0.47-1.72) 0.749
MEDAC IgA
Negative 49 89 1
Positive 10 14 1.3 (0.55-3.14) 0.563
ANIlab
Negative 29 59 1
Positive 30 44 1.39 (0.73–2.64) 0.318
MEDAC CP
Negative 2 22 1
Positive 57 81 7.74 (1.75–34.21 0.007
CT Infection (NAAT)
Negative 28 73 1
Positive 31 30 2.69 (1.39–5.24) 0.003
aThis table only includes women who had consistent results in all assays
(n = 162), 59 sub-fertile and 103 fertile women
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assays and NAAT results, particularly between NAAT,
MEDAC MOMP, and ANIlab. This supports the notion
that these assays are reporting serological responses to
CT and are not likely to be a consequence of non-
specific reactivity.
Discussion
The results of this study imply that up to half (51 % in-
fertile women positive for MEDAC MOMP) of women
who are sub-fertile in this population could have CT as a
cause or contributing factor. To our knowledge this is
one of the highest burdens of CT associated sub-fertility
reported to date. This is higher than most studies report,
even those conducted in fertility clinics, but is consistent
with a fertility clinic study in India that found a similar
prevalence [15]. This may be a reflection of the absence
of routine screening and treatment for CT infections in
this population.
A possible limitation of our study is that the sero-
logical results may be influenced by a higher number of
repeat infections given the high prevalence of infection
in this population. These repeat infections may lead to
higher positives in these assays which use absorbance
thresholds that have been designed on clinically defined
infertile cohorts, often in settings with a much lower
background prevalence. The MEDAC Infertile assay was
not significantly associated with sub-fertility in this
study. Nevertheless, the high prevalence of cHSP60 anti-
bodies (one of the components of the MEDAC test)
could suggest that chronic infections or sequelae are
high in this population. Most studies that found a sig-
nificant association had TFI as the specified measure for
infertility [9]. In this population we have limited
knowledge of the other fertility factors as this was a
village-based survey in the absence of any gynecological
investigations that would normally be conducted in a fer-
tility clinic. In addition it is of course possible, considering
the sensitivities of obtaining sexual behavior information
that some women were mis-classified with respect to sub-
fertility. The amount of sexual activity was of course not
the same for each woman, affecting their individual prob-
abilities of becoming pregnant.
The study findings indicated a higher fertility rate in
the older ages (although the inclusion criteria were lim-
ited to the most reproductive years). The higher fertility
in the older women is not that unexpected and is likely
because this study is based on sexually active women
who were all within the ideal reproductive age, so the
Fig. 2 Venn diagram to demonstrate concordance between serological assays and CT NAAT results. The diagram shows the number of
participants positive in each of the assays and those who were positive in more than one assay. The two MOMP assays (MEDAC IgG and ANIlab)
and NAAT results showed considerable concordance. The samples that were negative in all assays are also indicated on the figure, only the 162
samples that had a valid result in all of these assays are included in the Venn diagram
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longer the period of sexual activity the more likely the
women are to have conceived. Alternatively, this could
be explained by an increased desire of these women
(25–29 year olds) to achieve pregnancy leading to in-
creased sexual activity.
It was unexpected to find a significant correlation of
sero-positivity to C. pneumoniae with sub-fertility in this
population. It is difficult to determine if this is actually
serological cross reactivity (or a genuine association).
Serology to C. pneumoniae, or the presence of the or-
ganism, has been previously found to significantly cor-
relate with various diseases [19–21], but not with sub-
fertility. One possible explanation for this finding could
be that the infertile women in this population have tis-
sue lesions or adhesions in the fallopian tube that may
form a reservoir for the pathogen and perhaps the im-
mune response to this reserve of CP may exacerbate the
CT pathology that results in development of tubal sub-
fertility. This persistence in the scarring site could ex-
plain the high prevalence of CP serology that, whilst sig-
nificant, is not causal for sub-fertility. Alternatively, this
could be a chance result. Firstly, as the prevalence of
Chlamydia pneumoniae antibodies is very high (in both
fertile and infertile women), statistical analysis tends to
lead to an overestimation of the odds ratio. Secondly,
the number of participants included in the analysis is
relatively low (n = 233).
MEDAC MOMP and MEDAC CP were the only as-
says that significantly correlated with sub-fertility, sug-
gesting that whilst serology is a much more feasible
manner to measure possible chlamydial infertility in the
developing world setting the current assays may be con-
founded by the high prevalence, and only MEDAC
MOMP may be suitable.
Conclusions
The high prevalence of C. trachomatis infections in
Samoa is likely to be leading to high rates of preventable
sub-fertility in this population. The results reported here
using serological and epidemiological data collection in-
dicate that CT-associated sub-fertility could be a factor
for as much as half of the burden of sub-fertility in sexu-
ally active women in this reproductive age range in
Samoa.
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